Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019)
Cabaletta Bio's (CABA) quarterly Preferred Stock Liabilities came in at $98.0 million in Q3 2019, little changed quarter-over-quarter from $98.0 million in Q2 2019.
Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Cabaletta Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $98.0 million for Q3 2019.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $98.0 million in Q3 2019; TTM through Sep 2019 was $98.0 million, a N/A change from a year earlier, with the FY2018 full-year figure at $43.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $98.0 million in Q3 2019 per CABA's latest filing, from $98.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $98.0 million in Q2 2019 and bottomed at $43.9 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Cabaletta Bio | 184.38 Mn | 184.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 97.95 Mn |
| Jun 30, 2019 | 97.95 Mn |
| Dec 31, 2018 | 43.92 Mn |